Table 3 Best overall response
|  | Pralsetinib | Pralsetinib + Antiangio | Chemo | Chemo + Antiangio | Chemo + Immuno + Antiangio | Immuo + Antiangio | MKIs |
|---|---|---|---|---|---|---|---|
(n = 28) | (n = 3) | (n = 11) | (n = 8) | (n = 3) | (n = 1) | (n = 10) | |
Best response, n (%) | |||||||
 CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 PR | 15 | 2 | 4 | 2 | 0 | 1 | 0 |
 SD | 13 | 0 | 3 | 6 | 3 | 0 | 4 |
 PD | 0 | 1 | 4 | 0 | 0 | 0 | 6 |
 ORR, % | 53.6% | 66.7% | 36.4% | 25.0% | 0 | 1(1/1) | 0 |
 DCR, % | 100.0% | 66.7% | 63.6% | 100.0% | 3(3/3) | 1(1/1) | 40.0% |
PFS | |||||||
 Events, n (%) | 15 | 3 | 11 | 8 | 3 | 1 | 10 |
 Median, months (95% CI) | 16.03 | 3.20 | 2.87 | 6.90 | 7.40 | NA | 2.50 |
|  | (9.861–22.199) | (2.827–3.573) | (0.793–4.424) | (3.528–10.272) | (5.32-10.272) |  | (0.434–4.566) |
 One-year survival rate, % | 18 (64.3%) | 0 | 1 (9.1%) | 2 (25%) | 0 | 1 (1/1) | 1 (10%) |
 Two-year survival rate, % | 13 (46.4%) | 0 | 0 | 1 (12.5%) | 0 | 1 (1/1) | 0 |